Sign In
Buy NVCR
$16.15
+0.330 (+2.09%)
At Close: Jun 03, 2026
NovoCure (NVCR) Stock Is Trending Overnight — Here's What You Should Know
09:55pm, Wednesday, 11'th Feb 2026
NovoCure shares surged after FDA approval of Optune Pax for locally advanced pancreatic cancer.
Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar
06:33pm, Wednesday, 11'th Feb 2026
The Swiss biopharmaceutical company's shares surged in after-hours trading after it said the FDA approved its Optune Pax product.
U.S. FDA Approves Novocure's Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
05:54pm, Wednesday, 11'th Feb 2026
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax® for the treatment of adult patients with locally adva
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of “Hold” from Analysts
02:28am, Monday, 09'th Feb 2026
Shares of NovoCure Limited (NASDAQ: NVCR - Get Free Report) have earned an average recommendation of "Hold" from the seven ratings firms that are currently covering the company, Marketbeat.com reports
NovoCure Limited (NASDAQ:NVCR) Short Interest Up 20.0% in December
04:53am, Wednesday, 21'st Jan 2026
NovoCure Limited (NASDAQ: NVCR - Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 8,333,839 shares, a growth of 20
NovoCure Limited (NASDAQ:NVCR) Receives Average Rating of “Hold” from Analysts
02:08am, Thursday, 15'th Jan 2026
NovoCure Limited (NASDAQ: NVCR - Get Free Report) has earned an average recommendation of "Hold" from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One equities re
NovoCure Limited (NVCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
04:26pm, Wednesday, 14'th Jan 2026
NovoCure Limited (NVCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
07:00am, Monday, 12'th Jan 2026
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Novocure is a
NovoCure: 2026 Pipeline Outlook Makes This Stock A Speculative Buy
06:44am, Friday, 02'nd Jan 2026
Despite an expected 7% revenue growth for FY2025, NVCR stock price was cut in half in 2025 following the disappointing adoption of Optune Lua in the US and Germany. Yet, the company pipeline has multi
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference
07:00am, Monday, 22'nd Dec 2025
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on Janua
Edgestream Partners L.P. Increases Holdings in NovoCure Limited $NVCR
04:27am, Thursday, 04'th Dec 2025
Edgestream Partners L.P. raised its holdings in shares of NovoCure Limited (NASDAQ: NVCR) by 30.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commi
NovoCure Limited $NVCR Shares Purchased by American Century Companies Inc.
03:18am, Wednesday, 03'rd Dec 2025
American Century Companies Inc. raised its stake in shares of NovoCure Limited (NASDAQ: NVCR) by 1,354.7% during the second quarter, according to its most recent filing with the Securities and Exchang
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
07:00am, Monday, 01'st Dec 2025
BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously s
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference
07:00am, Wednesday, 26'th Nov 2025
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the 37th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2,
2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon
10:00am, Wednesday, 12'th Nov 2025
A biotech upstart and a life sciences giant could be compelling additions to an investor's portfolio. NovoCure is a high-risk but potentially high-reward bet on industry-changing technology.
